In $75M Deal, PacBio will Develop Clinical Dx Sequencing System and Assays for Roche | GenomeWeb

Pacific Biosciences today announced a $75 million agreement with Roche Diagnostics to develop and supply diagnostic products, including sequencing systems and consumables based on PacBio's single-molecule real-time sequencing technology.

Roche will have global rights to exclusively distribute the products in the field of human in vitro diagnostics, while PacBio will continue to market its current and future products for research use in all other markets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.